New LIH publication in Leukemia: understanding treatment-free remission in CML

• Multiomics Data Science
• Department of Cancer Research
• Cancer

Earlier this month, Multiomics Data Science Group researchers Maryna Chepeleva and Dr Petr Nazarov along with Dr Sébastien Rinaldetti from the CHL published their new article in the journal Leukemia.

The study investigated the molecular and immune factors associated with stable treatment-free remission and molecular relapse in chronic myeloid leukemia (CML) following treatment discontinuation. Using samples from 240 patients enrolled in the large European EURO-SKI study, the researchers identified important differences in immune activity between the two groups.

Their findings suggest that successful treatment-free remission is associated with coordinated communication between innate and adaptive immune cell populations. In contrast, patients who relapse show signs of disrupted immune communication. These results provide valuable new insights into the biological mechanisms behind treatment-free remission and could help improve future strategies for identifying patients who may be able to safely discontinue therapy.

“One of the most exciting aspects of this study is that it highlights the immune system as a key player in maintaining remission after treatment has stopped. By better understanding the biological mechanisms behind treatment-free remission, we hope to develop more personalized approaches to identify patients that are able to safely discontinue therapy“, said Maryna Chepeleva, lead author from the Multiomics Data Science Group at the LIH.

Funding & Collaborations:

This work was supported by the Luxembourg National Research Fund (grant PRIDE21/16763386/CANBIO2).